ALK and anaplastic large cell lymphoma: One pooled analysis showed that PTCL-NOS and ALK-ALCL patients without DUSP22 rearrangement could benefit from ASCT (36), indicating ALK-ALCL patients with DUSP22 rearrangement may be a potential transplant-exempt population.